Updated CheckMate -025 results demonstrate superior OS, ORR for Opdivo in RCC

Share on facebook
Share on twitter
Share on linkedin
Share on email
Share on print

The phase III CheckMate -025 study demonstrated that treatment with Opdivo (nivolumab) continues to deliver superior overall survival and objective response rates in patients with previously treated advanced or metastatic renal cell carcinoma, compared to those treated with everolimus.

To access this subscriber-only content please log in or renew your subscription.

Looking for IP Login? Our IP Login system is now automatic. If your institution has a site license, please log in from on site or via your VPN to access this content.

Login Subscribe

YOU MAY BE INTERESTED IN

Login